Exubrion Therapeutics Promotes Gregory Taglialatela to Chief Commercial Officer
Exubrion Therapeutics®, the company behind Synovetin OA®, has promoted Gregory Taglialatela, MBA, to Chief Commercial Officer, effective July 1, 2026. In his new role, Taglialatela will lead Exubrion’s commercial strategy…
